Introduction
Paracetamol (acetaminophen) and the nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in children for antipyresis and analgesia. The anti-inflammatory properties of the NSAIDs have, in addition, been used in such diverse disorders as juvenile idiopathic arthritis, Kawasaki disease and cystic fibrosis (1) (2) (3) (4) . The NSAIDs indomethacin and ibuprofen are also used to treat delayed closure of patent ductus arteriosus (PDA) in premature infants (5) . Paracetamol and NSAIDs are often given together for the management of pain or fever. Despite the widespread use of these medications there are few data comparing efficacy of these drugs. The combined effectiveness of paracetamol and a NSAID is insufficiently documented in children and it is unknown if there is synergy or additivity of effect when the two drugs are used together.
Litalien and Jacqz-Aigrain (6) have recently reviewed the risks and benefits of NSAIDs and paracetamol in children. Knowledge of individual drug pharmacokinetics (PK) and pharmacodynamics (PD) is essential to compare effectiveness. Pharmacokinetic age-related changes and covariate effects are poorly documented for many of the NSAIDs. Pharmacodynamic data are often a simple comparison of one drug to another without quantifying effect. There is a paucity of analgesia concentration-effect relationship data in children, although fever control (7) (8) (9) (10) and PDA closure (11) relationships are emerging. In order to use these drugs properly, effectiveness data must be balanced against the drugsÕ safety profiles. Currently this is not carried out and often the safety profile of one NSAID is extrapolated to another.
This current review examines the methods used to compare NSAIDs with paracetamol, the difficulties associated with such comparisons and the impact of drug side effects on dosing regimens in children.
Mechanism of action

NSAIDs
The NSAIDs are a heterogeneous group of compounds that share common antipyretic, analgesic and anti-inflammatory effects. Their major action is through inhibition of prostaglandin synthesis. The NSAIDs act by reducing prostaglandin biosynthesis through inhibition of cyclo-oxygenase (COX), which exists as two isoforms (COX-1 and COX-2). Most NSAIDs block the function of both isoenzymes to varying degrees (12) . The prostinoids produced by COX-1 isoenzyme protect the gastric mucosa, regulate renal blood flow and induce platelet aggregation. NSAID-induced gastrointestinal (GI) toxicity, for example, is generally believed to occur through blockade of COX-1 activity, whereas the anti-inflammatory effects of NSAIDs are thought to occur primarily through inhibition of the inducible isoform, COX-2.
Paracetamol
Paracetamol (N-acetyl-p-amino-phenol) has antipyretic and analgesic effects, but is lacking anti-inflammatory effects. The mechanism of action of paracetamol analgesia is multifactorial. It is a potent inhibitor of prostaglandin synthesis within the central nervous system but also acts peripherally by blocking impulse generation within the bradykininsensitive chemoreceptors responsible for the generation of nociceptive impulses. Paracetamol is also thought to have an analgesic effect by antagonising N-methyl-D D-aspartate (NMDA) and substance P in the spinal cord. Analgesic effect also involves an inhibitory action on spinal nitric oxide mechanisms. (13) (14) (15) .
Efficacy
The clinical effectiveness of a drug depends not on its potency (EC 50 ) but on its efficacy and its ability to reach the relevant receptors. Efficacy reflects the limit of the concentration-response relation on the response axis (16) . In therapeutics efficacy denotes the extent or degree of an effect that can be achieved in the intact patient. Pharmacological efficacy does not have the same meaning as effectiveness, although the two terms are sometimes incorrectly used interchangeably. Furthermore, therapeutic efficacy may be limited by the drug's propensity to cause a toxic effect.
Target concentration
Current paediatric dosing of paracetamol or NSAIDs is not based on rigorous efficacy data. Pharmacodynamic data are required to calculate dose. Calculation of the dose for an individual has the strongest theoretical support when based on the target concentration strategy (17) . This assumes that a target effect is required and the concentration needed to achieve that effect is predictable from PD factors. The dose is then predicted from the target concentration and pharmacokinetic factors.
Indomethacin target concentrations for PDA closure have been proposed (11) and therapeutic drug monitoring has been recommended to achieve ibuprofen target concentrations in children with cystic fibrosis (18) . However, target concentrations for analgesia in children remain poorly defined and some methods used to assess analgesic effectiveness or compare analgesic medications unrefined. Comparisons between NSAIDs and paracetamol often use doses extrapolated from adult data without paediatric PD or PK data to support them.
Methods used to assess the effectiveness of paracetamol or a NSAID
Comparison with local anaesthetic blockade
Inguinal herniotomy has been used as a surgical pain insult to compare postoperative pain relief from a NSAID to caudal bupivacaine (0.2-0.25%) regional blockade. Splinter et al. (19) showed similar analgesia after intravenous ketorolac 1 mgAEkg )1 and caudal blockade (n ¼ 164). Ryhanen et al. (20) demonstrsted children (n ¼ 240) given intramuscular diclofenac 1 mgAEkg )1 had improved late postoperative analgesia compared with caudal analgesia. Moores et al. (21) , using a lower dose of diclofenac 0.25 mgAEkg )1 given rectally, was unable to demonstrate any superiority (n ¼ 40). These data suggest that NSAIDs are an alternative to caudal blockade analgesia after herniotomy, but give little information about quantifying that analgesia. We can imply that the larger dose of intramuscular diclofenac, a route that has a higher relative bioavailability and lower absorption variability than rectal, is more effective for a longer duration than caudal bupivacaine. This is consistent with this drug's known long duration of action, attributable to effect site kinetics. Substantial intraarticular tissue concentrations of NSAIDs are attained after systemic administration and elimination half times are longer in synovial fluid than in plasma, contributing to their effectiveness in arthritis (22, 23) .
Comparison with morphine
Morphine is accepted as a standard analgesic in children (24, 25) and is often used for comparative studies with other analgesic medications. Studies comparing paracetamol or ketorolac (0.75-1 mgAE kg )1 ) with morphine (0.1 mgAEkg )1 ) for analgesia after tonsillectomy (26) , strabismus surgery (27) or general surgery have demonstrated similar degrees of analgesia with reduced emesis with some increased bleeding in children given ketorolac. Morphine, however, may not be the ideal drug to use as a standard because of variability of PK, PD and effect compartment equilibration half-time (T eq ) (24, 28, 29) . A concentration-response relationship has not been described. Maunuksela et al. (30) attempted to address this issue by titrating either morphine 0.1 mgAEkg )1 or ketorolac 0.2 mgAEkg )1 to effect after paediatric surgery. Analgesia was similar in both groups, but children given ketorolac initially required more doses than those children given morphine. This could reflect a lower potency (1 : 1-1 : 3) or a larger T eq for ketorolac. Morphine did not maintain its analgesic effect for as long as ketorolac, again reflecting ketorolac's longer duration of effect.
Direct comparison of NSAIDs with paracetamol
Maunaksela and Olkkola (31) have suggested that 1 mgAEkg
large number of studies have been performed comparing paracetamol with a NSAID for either analgesia or antipyresis in children. Most show either similar effect or slight superior effect with a NSAID (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) . One major criticism of such studies is that paracetamol dosing may not be equipotent with that of the NSAID used. Paracetamol doses of 10 mgAEkg )1 p.o. given either as a single dose (32, 36, 40) or three to four times daily (35, 38, 39) may not achieve concentrations associated with analgesia or antipyresis or may achieve these concentrations only after two to three doses (45) . Assessment of effect may be made too early -before peak concentrations in the effect compartment are reached (32, 33) . If the T eq of the NSAID is smaller than that of paracetamol then earlier assessments will favour the NSAID. The duration of effect for the NSAID may be longer than that of paracetamol. Improved analgesia in children given NSAIDs during this later study period will bias results (37) . PK vary with age. Clearance in a 1-year-old child is greater than in an 8-year-old child. There are considerable differences in absorption and relative bioavailability between rectal and intravenous formulations. Serum concentrations and consequent effect will vary with age and formulation.
Morphine sparing 
Number needed to treat
The lack of direct comparisons makes it hard to judge the relative efficacy of analgesics. Relative efficacy may be determined indirectly from comparisons of each analgesic with placebo. A method that converts mean values for pain relief into dichotomous information (number of patients with at least 50% of maximum total pain relief from pain relief scales over 4-6 h) has been validated (50) (51) (52) . This method has been used to produce a quantitative systematic review of the relative analgesic efficacy of single oral doses ibuprofen and diclofenac in postoperative pain, using the Number Needed to Treat (NNT) as a descriptor of effectiveness (53) . A single dose of ibuprofen 400 mg given to adults had an NNT of 2.7 for at least 50% pain relief compared with placebo (53) . This means that one out of every three patients with pain of moderate to severe intensity will experience at least 50% pain relief with ibuprofen, which they would not have had with placebo. It is possible to form a doseresponse relationship from these data ( Table 1) . Rational decisions about dosing equivalence can also be made. Unfortunately paediatric NNT tables are unavailable.
Such adult NNT data support clinical experience showing paracetamol 1000 mg (NNT 4.6, 95% CI 3.8-5.4) has similar analgesic effectiveness to aspirin 1000 mg (NNT 4.0, 3.2-5.4). Ibuprofen 400 mg and diclofenac 50 mg are more effective than paracetamol and aspirin 1000 mg. They are also more effective than several other commonly used analgesics including some with an opioid component, e.g. dextropropoxyphene 65 mg plus paracetamol 650 mg (NNT 4.4, 3.5-5.6), tramadol 100 mg (NNT 4.8, 3.8-6.1) and dihydrocodeine 30 mg (NNT 9.7, 4.5 to >10000) (53) .
The 95% confidence levels for some of NNT estimates are broad. One contributor to this range is PK variability. For example, Prescott (54) , in a study of 43 adult convalescent patients, reported an 80-fold range in concentrations 1 h after 500 mg tablets. A concentration-response relationship eliminates PK variability contained in the dose-response relationship.
The sigmoid E max model
The relation between drug concentration and effect may be described by a hyperbolic curve according to the equation
Where E0 is the baseline response, E max is the maximum effect change, Ce is the concentration in the effect compartment, EC 50 is the concentration producing 50% E max and N is the Hill coefficient defining the steepness of the concentration-response curve ( Figure 1 ). The Sigmoid E max model. The steepness of the slope is determined by the Hill coefficient (N). Observed effects may not be directly related to serum concentration. There may be a delay because of transfer of the drug to effect site (D D-tubocurare at the neuromuscular junction), a lag-time (furosemide at the luminal surface of the renal tubule), physiological response (antipyretic action mediated through the hypothalamus), active metabolite (caffeine from theophylline in premature neonates) or synthesis of physiological substances (warfarin inhibition of vitamin K epoxidase). (55) The effect compartment concentration is not the same as the blood or serum concentration. A T eq between serum or blood and effect compartment can be used to describe this time delay. By simultaneously solving PK and PD equations it is possible to estimate effect compartment concentrations.
Effect = E0 + (E max
×
Difficulties comparing drugs in children
Ethical issues
Review Boards and Ethics Committees view children differently than adults. It is not considered ethical to enrol children in trials solely for the good of future patients. Developmental issues, the inability to give informed consent (56) , blood sampling requirements (57) , and questions about payment for research participation (58) make paediatric research more difficult than adult. These issues have recently been reviewed in Paediatric Anaesthesia in a series of three reviews, examining the changes in the law in the last 10 years in relation to ethics and the practice of paediatric anaesthesia. These reviews cover, in a practical question and answer format, the topics of consent, research, intensive care and organ donation issues in children (59-61).
Type of pain
An outcome measure is vital to describe PD. However, acute pain is a complex sensation composed of elements beyond simple pathophysiology. Behavioural, cultural and psychological aspects contribute to its expression. It may vary between individuals depending on past experiences and duration. Early painful memories as a neonate may lead to abnormal behavioural patterns or altered sensory processing in later life (62) . Visceral pain is quite different in nature from somatic pain. NSAIDs may better control visceral pain because of bladder spasm that is contributed by prostaglandin (63, 64) . Similarly, NSAIDs may improve bone and joint pain better than paracetamol. Comparison of treatment modalities after different types of pain insults such as in children presenting for day-stay surgery may not be reasonable. The threshold at which pain requires management also varies between individuals. Gauthier et al. (65) have reported a pain treatment threshold of 5.3 units (VAS, 0-10) with a coefficient of variation of 30% after minor uncomplicated surgery in children.
Placebo effects
The placebo effect accounted for a mean pain reduction of 5.6 (VAS, 0-10) at 3 h in a recent study investigating paracetamol PD after tonsillectomy (66) . The placebo response in that study reflected a combination of placebo effect, natural pain resolution, behavioural pain coping mechanisms and our inability to discriminate pain from emergence phenomena in the early postoperative period (67) . Following emergence from anaesthesia, children were reunited with family, given access to video movies and allowed flavoured ice. These are all important contributors to the relief of pain that was described as the placebo response. Differentiating this placebo response from drug effect can be difficult. Ethical considerations often preclude a group of children randomized to receive a placebo drug. Korpela et al. (49) report that 10% of children given a placebo drug required no rescue morphine after day-stay surgery. The continuing use of placebo controls has been strongly argued against in the literature (68).
Pain and temperature fluctuations
Pathological states may resolve, worsen or remain static and the interpretation of the impact of medication on these changes can be complex (69) . Neither pain nor temperature is constant over time. Pain waxes and wanes. Tonsillectomy pain, a model often used to investigate analgesic medication in children resolves over 2 weeks. Pain scores in children appear to decrease after only 3 days, but are often worse on the second or third day (70) (71) (72) . Fever can be cyclical in nature or affected by environmental factors such as swaddling, ambient temperature or radiant heat loss through a nearby window.
Age related pain scoring and comparisons between age groups
Children aged over 8 years can use visual-analogue pain scales. Between the ages of 3 and 8 years face scales or colour analogue scales are commonly used (73) (74) (75) . Discordance between these two scales has been reported within this age band (76) . Pain assessment may vary between caregivers, researchers and nurses (77) . Behavioural observational scales are used in neonates, infants and children younger than 4 years. These may under represent the intensity of persistent pain (76) . Physiological indexes of pain may be nonspecific. For example, hypovolaemia, hypoxia or drugs, rather than pain may cause tachycardia (78) .
The assessment of pain at different ages involves different scoring systems with assessment values that may not be longitudinally comparable. Pain in neonates cannot be directly compared with that in older children. The pain sensitivity and response in a neonate may be different from an older child. Descending inhibitory pathways develop later than afferent excitatory pathways in the premature neonate (79) . There is a lower threshold of the cutaneous flexion reflex (80, 81) . Prolonged windup and hyperalgesia occurs following neonatal skin wounds and may be associated with excessive nerve sprouting because of nerve growth factor (82) .
Drop outs
Patients who receive rescue medication and are withdrawn from a study may introduce additional bias as the remaining study patients are those who do not have such severe pain; the reason for their reduced analgesia may not be solely pharmaceutical (83) .
PK covariates -age and size modelling
The per kilogram and surface area models may be inappropriate for scaling small children to adults (84) . It is possible to show that in almost all species including humans, the log of basal metabolic rate (BMR) plotted against the log of body weight produces a straight line with a slope of 3/4. West et al. (85, 86) have used fractal geometry to mathematically explain this phenomenon. A great many physiological, structural and time related variables scale predictably within and between species with weight exponents of 0.75, 1 and 0.25, respectively. These allometric Ô1/4 powerÕ models can be applied to PK parameter estimates in children, e.g. clearance (0.75), half-life (0.25), volume of distribution (1) . A dose (mgAEkg )1 ) given to a 1-year-old child will have lower serum concentrations than the same dose (mgAEkg )1 ) given to a 10-year-old child because
is greater in the younger child.
Dose-response relationships will consequently change with age unless PK parameters are standardised for size.
The first few years of life are a time of growth and maturation of enzymatic processes. By choosing weight as the primary covariate, the secondary effects of age can be investigated. There are few biological models for the effect of age on clearance or apparent volume, but first order processes, which are common in biology, have been assumed (87) . Covariates such as renal function, gender, concomitant drug therapy, illness can all be investigated and their effect quantified.
Chirality
Many NSAIDs exhibit stereoselectivity. Ketorolac, for example, is supplied and administered as a racemic mixture that contains a 1 : 1 ratio of the R(+) and S()) stereoisomers. Pharmacological activity resides almost exclusively with the S()) stereoisomer. Clearance of the S()) enantiomer was four times that of the R(+) enantiomerin (6.2 vs. 1.4 mlAEmin )1 kg )1 ) in children 3-18 years (88).
Terminal half-life of S())-ketorolac was 40% that of the R(+) enantiomer (107 vs. 259 min), and the apparent volume of distribution of the S()) enantiomer was greater than that of the R(+) form (0.82 vs. 0.50 lAEkg )1 ). Recovery of S())-ketorolac glucuronide was 2.3 times that of the R(+) enantiomer. Because of the greater clearance and shorter half-life of S())-ketorolac, pharmacokinetic predictions based on racemic assays may overestimate the duration of pharmacological effect. Enantiomeric pharmacokinetic differences may be explained by stereoselective plasma protein binding and selective glucuronidation of the S()) enantiomer (88) .
PK and PD variability
Population PK parameter estimates are associated with considerable variability. Typical values of 50% for compliance with medication regimens, 30% for absorption, 10% for tissue distribution, 50% for metabolic elimination and 20% for renal elimination are reported (89) . These parameter variabilities contribute to the large concentration range seen after a rectal paracetamol dosing ( Figure 2 ) (90). An extreme example of clearance variability is demonstrated by codeine. The O-methylation (cytochrome P450 enzyme CYP2D6) of codeine to morphine is lacking in 7% of Caucasians (91, 92) ; contributing to the observed NNT 95% CI for dihydrocodeine 30 mg of 4.5 to >10000 (53) . The use of concentration to link dose and effect allows PK variability to be separated from PD variability. The reduction in total variability produced by the removal of the PK component has been estimated to be 50% or greater. Pharmacodynamic (concentration-effect) variability also exists. The contribution of variability because of distribution from the blood to the site of action will depend largely on changes in perfusion of target tissue (5-50%) and efficacy variability (30%) also exist. The observed response may not be a direct consequence of drug-receptor binding, but rather through intermediate physiological mechanisms (e.g. antipyretics, angiotensin converting enzyme inhibitors). A typical value for this variability is 30% (89) .
Many clinical studies in which paracetamol is compared with another analgesic are destined either to fail to show a difference between the two analgesic treatments or to have inadequate power because pain score reporting methods, the pain stimulus and PK and PD parameters all have large variability.
Population modelling methods
The method used to estimate population parameters might also have an impact on results. Three methods are commonly used -the naïve pooled data, the standard two-stage and the ÔtrueÕ population approaches.
The naïve pooled data approach may be satisfactory if data are extensive for each individual and there is only minor inter-individual variability, but may result in misrepresentation if data are few (93) . It is possible to Ôwash outÕ any observed effect. For example, if a population is randomized to receive either drug A or drug B and serum drug concentrations and pain scores after a surgical insult measured, then no difference in effect may be noted. Both drugs will result in some patients with high concentrations and good effect and some with low concentrations and poor effect. However, the naïve-pooled results will wash out these doseconcentration and concentration-effect responses. Mean data may reflect no difference in the two populations.
The standard two-stage approach ignores the imprecision in the estimate of an individual's structural parameter. Further, if the estimates are not based on a similar number of measurements for each individual, or if the response in one individual is much more variable than another, some form of weighting is required.
Population modelling using mixed effect models (e.g. NONMEM), in which differences in parameters between subjects are modelled using distributions for these parameters, are superior. Explanatory covariates can also be introduced that explain part of the inter-individual variability. Interpretation of truncated individual data or missing data is also possible with this type of analysis (94, 95) . Sigmoid E max models for antipyresis and analgesia
Antipyresis
There are few studies describing the PD of a NSAID and paracetamol using the same population and study design. Ibuprofen is the most common NSAID antipyretic studied (7-10). Kelley et al. (9) studied children (n ¼ 39; age range, 11 months to 11.5 years) randomly selected to receive a single dose of either 6 mgAEkg )1 of liquid ibuprofen or 10-15 mgAEkg )1 of liquid paracetamol (mean dose given, 11.6 SD SD 0.7). Temperature reduction for the ibuprofen dose was significantly different than that of the paracetamol dose at later time points. Naïve pooled data from Kelley et al. (9) have been modelled using a first order absorption, first order elimination PK model with delayed effects accounted for by an effect compartment model using MKMODEL (96, 97) . Effect compartment time-concentration relationships are shown in Figures 3a (paracetamol) and 4a (ibuprofen). Pharmacodynamic parameter estimates are shown in Table 2 . The effect compartment concentration-response relationship is shown in Figures 3b (paracetamol) and 4b (ibuprofen) . The maximal response cannot be estimated with any certainty because higher doses were not explored, although an E max of 5.4°F (3°C) would be clinically reasonable. Several studies have shown fever reductions of up to 3°F after either paracetamol (10-12.5 mgAEkg )1 ) or ibuprofen (5-10 mgAEkg )1 ) (39, 40, 98) . Importantly, the shapes of the two curves are quite different. The paracetamol curve is initially concave upward while ibuprofen has an almost linear relationship. Consequently at lower concentrations ibuprofen will generate a greater response than paracetamol. In order to compare the efficacy of these two antipyretic drugs we require response data at higher concentrations than those currently reported do. The dose given and where the subsequent effect compartment concentration lies on the response curve will influence observed effect. Interpretation of antipyretic data is more complicated than the above analysis of data from Kelley et al. (9) suggests. Brown et al. (7) have reported a linked population PK-PD model for antipyresis using mixed effects models. The addition of a slope and/or a sinusoidal cyclic function to the Sigmoid E max component was required to fit the PD data satisfactorily. The initial temperature also influenced the antipyretic effect.
The interpretation of the concentration-response relationship is confounded by the disease process, initial temperature, dosing regimens and fever fluctuation ensuring that direct comparison between paracetamol and ibuprofen is difficult. A large number of studies have suggested that the clinical effectiveness of these two drugs is similar. No clinical trials have been conducted that demonstrate superior effect when both drugs are used compared with one alone.
Analgesia
Similar considerations apply to analgesic models. Pain fluctuations, pain type and placebo effects complicate interpretation. NSAID concentrationresponse relationships have been described in adults (99-104). Mandema et al. (99) studied patients (n ¼ 522) given a single oral or intramuscular administration of placebo or a single intramuscular dose of 10, 30, 60, or 90 mg ketorolac for postoperative pain relief after orthopaedic surgery. Mixed effects models were used. Pain relief was found to be a function of drug concentration (E max model), time (waxing and waning of placebo effect), and an individual random effect. The EC 50 and T eq were 0.37 mgAEl )1 and 24 min (Table 3 ). Only 25% of the patients achieved adequate pain relief with placebo. The concentration-response relationship is shown in Figure 5 . Anderson et al. (66) investigated paracetamol PD using mixed effects modelling after tonsillectomy in 182 children aged 9.0 (SD SD 3.0) years and weight 37.9 (SD SD 16.6) kg. Placebo effects and drug effects were modelled by effect site concentration models. A one-compartment model with first order input, lag time and first order elimination was used to describe the population PK of paracetamol, standardized for size with allometric models. PD population parameter estimates (population variability CV) for an E max model, in which the greatest possible pain relief (VAS 0-10) equates to an E max of 10, were E max 5.17 (64%) and EC 50 9.98 (107%) mgAEl )1 (Table 3 , Figure 6 ). The T eq of the analgesic effect compartment was 53 (217%) min. A target concentration of 10 mgAEl )1 was suggested for tonsillectomy pain (66) . Any comparison between paracetamol and ketorolac using these data is difficult. Ketorolac was studied in adults after orthopaedic surgery, paracetamol in children after tonsillectomy. The T eq of ketorolac appears shorter than paracetamol (24 vs. 53 min), suggesting earlier effect. Ketorolac also appears to have greater efficacy. However, there are no studies comparing concentration-response curves for a NSAID and paracetamol in children after the same pain insult. Our knowledge remains limited.
Safety issues
Paracetamol
The maximum dose possible is dictated not by PK-PD considerations, but by concerns about paracetamol induced hepatotoxicity.
Chronic use of paracetamol
There has been a reticence among practitioners to prescribe doses of paracetamol greater than 90 mgAEkg )1 AEday )1 (105) . Paracetamol overdose results in increased production of highly reactive electrophilic arylating metabolites by the hepatic cytochrome P-450-dependent mixed function oxidase enzyme system (CYP2E1). (106) The toxic metabolite of paracetamol, N-acetyl-p-benzoquinone imine (NAPQI) (107), binds to intracellular hepatic macromolecules to produce cell necrosis and damage. Paracetamol concentrations may rise in paediatric patients with low clearance after regular doses of 15 mgAEkg )1 4 h (108). There is adult evidence of glutathione depletion in adult volunteers given doses of 0.5 and 3 g paracetamol separated by 4-10 days (109). Significant hepatic and renal disease, malnutrition and dehydration increase the propensity for toxicity. Medications that induce the hepatic P450 CYP2E1, 1A2 and 3A4 systems (e.g. phenobarbitone, phenytoin, and rifampicin) may also increase the risk of hepatotoxicity. It is currently impossible to predict which individuals have an enhanced susceptibility to cellular injury from paracetamol. The coingestion of therapeutic drugs, foodstuffs or other xenobiotics has potential to induce these enzymes (110) . The influence of disease on paracetamol toxicity is unknown. It has been speculated that ingestion of paracetamol increases the potential for liver injury by another cause, such as a viral agent (111) . More recently, hepatotoxicity causing death or requiring liver transplantation has been reported with doses above 75 mgAEkg )1 AEday )1 in children and 90 mgAEkg (110, (112) (113) (114) . It is possible that even these regimens may cause hepatotoxicity if used for longer than 2-3 days (110). These reports (110, (112) (113) (114) and others from Australia (115, 116) and Scotland (117) may show abnormalities in liver function. It is unknown if there is a difference in the propensity to toxicity between those given paracetamol for fever and those given paracetamol for postoperative analgesia.
Single dose of paracetamol
The plasma concentration associated with toxicity after a single dose of paracetamol in children is extrapolated from adult data. The Rumack-Matthew (119) paracetamol toxicity nomogram is widely used to guide management of paracetamol overdose in adults and children. This nomogram was derived from a study by Prescott et al. half-life was less than 4 h in all patients without liver damage.
Clearance is a nonlinear function of weight, while volume is a linear function of weight. Dose is usually expressed as a linear function of weight. The 4-h concentration is determined by clearance, not volume in children, because absorption is rapid after oral elixir. As a consequence younger children (1-6 years) require larger doses (225 mgAEkg )1 ) than older children and adults (150 mgAEkg )1 ) to achieve similar concentrations at 4 h (121, 122) . This has been demonstrated in animals. Young rats have a higher median lethal dose than older rats (123) . More drug is required to produce a hepatotoxic reaction (123) . Young children under the age of 6 years are thought to be less susceptible to toxicity than older children and adults (119) . Less than 5% of children below 6 years with paracetamol concentrations above the Rumack-Matthew treatment line will develop transient hepatic abnormalities (124) . This may, in part, be attributable to the shorter half-life seen in children. In addition, young rats have been reported to have an increase in the rate of glutathione synthesis compared with older rats, as well as a capacity to increase glutathione levels after depletion (125) . Glutathione may then provide increased detoxification.
Neonates can produce hepatotoxic metabolites (e.g. NAPQI), but there are suggestions of a lower activity of cytochrome P-450 in neonates. This may explain the low occurrence of paracetamol-induced hepatotoxicity seen in neonates (126, 127) , despite reports of high serum concentrations (75, 360 mgAEl )1 )
in new-born neonates (126, 128) . Placental transfer from the mother achieved these concentrations.
NSAIDs
The NSAIDs have potential to cause GI irritation, blood clotting disorders, renal impairment and bronchoconstriction (129, 130) -effects postulated to be related to COX-1/COX-2 ratios, although this concept may be an oversimplification (131, 132) . For example, the COX-2 inhibitors rofecoxib and celecoxib produce qualitative changes in urinary prostaglandin excretion, glomerular filtration rate, sodium retention, and their consequences similar to nonselective NSAIDs. COX-2 is constitutively expressed in renal tissues of all species. It seems unlikely that these COX-2 inhibitors will offer renal safety benefits over nonselective NSAID therapies. It is reasonable to assume that all NSAIDs, including COX-2-selective inhibitors, share a similar risk for adverse renal effects (133) .
Renal effects
The effect of short-term treatment with NSAIDs on healthy kidneys is negligible. Large studies involving ibuprofen (134) (135) (136) and ketorolac (137) have shown little risk. Similar data are reported in children suffering juvenile rheumatoid arthritis (JIA) given NSAIDs as long-term treatment (138, 139) . However, renal compromise is described in children compromised by dehydration, hypovolaemia, hypotension or preexisting renal disease (140) (141) (142) (143) (144) (145) . NSAIDs may also potentiate the toxicity of other drugs such as aminoglycosides and cyclosporin (146, 147) .
Gastrointestinal effects
Adverse GI effects are significant in adults, particularly in those with peptic ulcer disease, H. pylori or advanced age (148) (149) (150) . The risk of acute GI bleeding in children given short-term ibuprofen was estimated to be 7.2/100 000 (CI 2-18/100 000) (134, 136) and was not different from those children given paracetamol. Similar data are reported in children given ketorolac for acute pain (144) . The incidence of clinically significant gastropathy is comparable with adults in children given NSAIDs for JIA (151, 152) , but gastro-duodenal injury may be very much higher (75%) depending on assessment criteria (e.g. abdominal pain, anaemia, endoscopy) (153) .
Bleeding propensity
The commonly used NSAIDs such as ketorolac, diclofenac, ibuprofen and ketoprofen have reversible antiplatelet effects, which are attributable to the inhibition of thromboxane synthesis. This side effect is of concern during the perioperative period (154, 155) . Bleeding time is usually slightly increased, but in most patients it remains within normal limits in children with normal coagulation systems (156) (157) (158) . There is conflicting evidence of the potential for increased surgical-site bleeding after tonsillectomy but, for other types of paediatric surgery, numerous clinical studies have confirmed that the NSAIDs are not associated with increased bleeding (46, (159) (160) (161) .
Studies involving the use of ketorolac analgesia for tonsillectomy have fuelled the debate against NSAID use in the perioperative period for this procedure. Several prospective (155, 162) and retrospective studies (26, 163, 164) reported increased bleeding in children given approximately 1 mgAEkg )1 ketorolac iv preoperatively or intraoperatively. Other authors were unable to demonstrate increased bleeding after tonsillectomy (165) (166) (167) . The increased bleeding may be attributable to the dose used and whether it is given preoperatively or postoperatively. Strom have been used (168, 169) with varying effects on bleeding (168) (169) (170) . Ketoprofen is not recommended in many countries because of insufficient efficacy and tolerability data. Diclofenac (38, 46, (171) (172) (173) and ibuprofen (42, 174, 175) appear to have, on balance, favourable profiles. Propensity to bleeding is reduced compared with ketorolac, but no therapeutic target concentrations for diclofenac (23) or ibuprofen have been defined.
Conclusions
NSAID and paracetamol doses are often compared without the PD and PK knowledge needed to support them. Pharmacodynamic models are needed to compare drugs and to predict the target concentration for a given target effect (176) . We need to define what target effect and consequent target concentration is required in different pain circumstances for the different drugs. The dose needed to achieve the target concentration can then be predicted from PK (and covariate) information (177) . Safety issues may limit the target concentration possible, as with paracetamol and ketorolac. Efficacy of the two drugs may be similar, but concerns about side effects may limit dose and consequent clinical effect achievable.
In recent years, paracetamol PK and PD in children have been reexamined. Much work remains undone, particularly for neonatal pain (178) . A pharmacodynamic model for postoperative tonsillectomy pain has been suggested (66) , but other types of pain stimuli or age-related differences have not been examined. Despite the introduction of the specific COX-2 inhibitor NSAIDs (132, 179, 180) , large holes remain in our PK-PD understanding of commonly used NSAIDs in children. Efficacy may vary with age or pain type. Target concentrations are undefined. Limited data exist concerning PK or agerelated changes for commonly used NSAIDs. Dose is often defined by toxicity data that may effect subpopulations only. The reason why some children suffer toxicity while others are unaffected is unknown, even for paracetamol. Concentrationresponse curves are wanting for these common analgesic drugs and without these PD data it remains difficult to directly compare the effectiveness of the NSAIDs to paracetamol.
